L3VLUP
ProSign in

SOLV in the 13F filings

Solventum Corp · CUSIP 83444M101

Sector · Medical devices and instrumentsTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Surgical, medical and electromedical devices
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024
Quarter end
30 Jun 2025
the date the book describes
Filed
15 Aug 2025
latest of these filings; the earliest 13 Aug 2025
Managers listing it
4
at least, of 95 tracked, among listed positions
Comparable managers
95
filed both Q1 2025 and Q2 2025; 4 listed it in both
Shares listed
10,578,364
combined, among listed positions
Reported value
$802m
combined, at the quarter end

Among the 95 comparable managers: 0 buyers (opened or added shares) and 5 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -1,605,962.

Managers listing SOLV in Q2 2025

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2025, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

4 of 4 holders

ActionFiling
Trian Fund Management LP8,462,819$642m16.93%Held014 Aug 2025 (the filing on sec.gov)
Arrowstreet Capital LP1,319,800$100m0.07%Trimmed-139,81213 Aug 2025 (the filing on sec.gov)
AQR Capital Management LLC780,565$59munder 0.1%Trimmed-361,56414 Aug 2025 (the filing on sec.gov)
Winton Group Ltd15,180$1.2m0.06%Trimmed-1,34614 Aug 2025 (the filing on sec.gov)

Largest increases and reductions, by shares

Q1 2025 to Q2 2025, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (2)

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
8 in Q3 2024 to 4 in Q2 2026

Tracked managers listing it, at least.

035810Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
SOLV by quarter
QuarterHoldersReported valueBuyersSellers
Q1 20242$4.5m20
Q2 20249$532m90
Q3 20248$863m43
Q4 20245$829m35
Q1 20256$925m23
Q2 20254$802m05
Q3 20257$769m51
Q4 20259$821m2513
Q1 20266$648m1621
Q2 20264$655m2113

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

SOLV and LLY →SOLV and JNJ →SOLV and VRTX →Choose a stock to compare with SOLV →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own SOLV, latest filings →Back to the 13F Explorer →